A recent network meta-analysis investigated the mid- to long-term metabolic effects of antipsychotics in randomized controlled trials of 13 weeks’ duration or longer in patients with schizophrenia.
A new oral antifungal (oteseconazole) specifically indicated for the treatment of RVVC was approved
in the United States in April 2022 and is currently on fast-track, priority review by Health Canada.